Skip to main content

Akiko Chiba

Associate Professor of Surgery
Surgical Oncology

Overview


Dr. Akiko Chiba is an Associate Professor of Surgery at Duke University Medical Center and Associate Program Director of Duke Breast Surgery Fellowship Program. She is a breast surgical oncologist who cares for patients with breast cancer, benign breast diseases and those with an increased risk of breast cancer. Her clinical interests include young patients with breast cancer, genetic mutation carriers, and de-escalation of surgical treatment after neoadjuvant therapies. She is also studying the role of microbiome in breast cancer and how modulation of microbiome could be used to improve patient outcome. 

In addition to her role at Duke Cancer Institute, Dr. Chiba serve as an advisory board member of Breast and Gyn Oncology System of Excellence with National Oncology Program Office, Veterans Health Administration. This is a national program to improve care for breast and gynecologic cancer of veterans. She is also the lead physician for National Teleoncology High Risk Breast Cancer Clinic. On the national level, she serves on the Breast Committee for Alliance for Clinical Trials in Oncology, Co-Chair of Editorial Committee for Association of Women Surgeons, and Vice-Chair of Member Engagement Committee for American Society of Breast Surgeons.

Office Hours


Please contact via email or contact administrative staff at 919-681-9156 for availability.

Current Appointments & Affiliations


Associate Professor of Surgery · 2024 - Present Surgical Oncology, Surgery
Member of the Duke Cancer Institute · 2022 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study.

Journal Article Breast Cancer Res Treat · July 2025 BACKGROUND: Neoadjuvant therapies can result in pathologic complete response (pCR) in patients with breast cancer, which can be predictive of long-term outcomes. Patients with estrogen receptor positive (ER +) tumors may receive either neoadjuvant chemothe ... Full text Link to item Cite

The association of race and ethnicity with risk-reducing mastectomies in patients with non-BRCA mutations.

Journal Article Am J Surg · June 18, 2025 INTRODUCTION: We compared rates of risk reducing mastectomies (RRM) in patients with breast cancer (BC)-related pathogenic variants. METHODS: Female patients ages ≥18 with a BC-related pathogenic variant, without a concurrent or prior BC diagnosis, were id ... Full text Link to item Cite

ERBB2-Low Expression by Race and Ethnicity Among Patients With Triple-Negative Breast Cancer.

Journal Article JAMA Netw Open · June 2, 2025 IMPORTANCE: Racial and ethnic disparities in pathologic complete response (pCR) and overall survival (OS) have been reported in patients with triple-negative breast cancer (TNBC). In addition to socioeconomic factors and access to care, differences in tumo ... Full text Link to item Cite
View All Publications

Education, Training & Certifications


St. George's University, School of Medicine (West Indies) · 2009 M.D.
The George Washington University · 2003 B.S.